Bali Kintamani Coffee (Coffea arabica 'Bali Kintamani')
Bali Kintamani Coffee (Coffea arabica 'Bali Kintamani') is an Indonesian specialty arabica cultivar grown in the volcanic highlands of Bali, containing chlorogenic acids (4.69–11.21%) that act as primary antioxidant and anti-inflammatory compounds. Its caffeine content (0.98–1.20%) stimulates the central nervous system by blocking adenosine A1 and A2A receptors, while co-occurring flavonoids and tannins contribute additional free radical scavenging activity.

Origin & History
Bali Kintamani coffee is a cultivar variant of Arabica coffee (Coffea arabica) grown specifically in the high-altitude Kintamani region of Bali, Indonesia. The coffee beans undergo standard processing methods including fermentation, during which bioactive compounds like chlorogenic acid develop, with levels ranging from 4.69-11.21% depending on fermentation conditions.
Historical & Cultural Context
While Kintamani coffee is noted as 'one of the most popular coffees in the world due to its specific taste,' no information about traditional medicinal use is documented in the available research. Historical or traditional medicinal applications specific to this cultivar are not established.
Health Benefits
• Antioxidant activity through chlorogenic acid content (4.69-11.21%) - Evidence quality: Laboratory analysis only • Central nervous system stimulation via caffeine content (0.98-1.20%) - Evidence quality: Known mechanism for coffee generally • Free radical scavenging from flavonoids and tannins present - Evidence quality: Phytochemical profiling only • Potential metabolic support from chlorogenic acid - Evidence quality: No clinical studies available • Possible cardiovascular benefits from polyphenol content - Evidence quality: No specific clinical data
How It Works
Chlorogenic acids in Bali Kintamani Coffee—primarily 5-caffeoylquinic acid—inhibit glucose-6-phosphatase activity, slowing hepatic glucose release, and upregulate Nrf2/HO-1 antioxidant pathways to neutralize reactive oxygen species. Caffeine competitively antagonizes adenosine A1 and A2A receptors in the brain, increasing dopaminergic and noradrenergic neurotransmission to enhance alertness and reduce perceived fatigue. Flavonoids and condensed tannins donate hydrogen atoms to free radicals, interrupting lipid peroxidation chain reactions and chelating pro-oxidant metal ions such as Fe²⁺ and Cu²⁺.
Scientific Research
No human clinical trials, randomized controlled trials (RCTs), or meta-analyses specific to Bali Kintamani coffee were found in the available research. The existing studies consist solely of chemical composition analyses and phytochemical profiling rather than clinical efficacy data.
Clinical Summary
Direct clinical trials on Bali Kintamani Coffee as an isolated cultivar are absent from the published literature; existing evidence is derived from laboratory phytochemical analyses and in vitro assays characterizing its antioxidant capacity. Studies measuring the cultivar's DPPH radical scavenging activity and total phenolic content confirm meaningful antioxidant potential, but no randomized controlled trials with human participants have been conducted on this specific variety. The well-established body of clinical research on Coffea arabica generally—spanning hundreds of trials with thousands of participants—supports benefits for alertness, metabolic health, and reduced all-cause mortality, but these findings cannot be directly extrapolated to Kintamani without cultivar-specific data. Evidence quality for this cultivar's unique health claims remains at the level of laboratory analysis only.
Nutritional Profile
Bali Kintamani Coffee (Coffea arabica 'Bali Kintamani') nutritional composition is characterized primarily through green bean and roasted bean analyses. Bioactive compounds dominate the profile: chlorogenic acids (CGAs) range from 4.69–11.21% dry weight in green beans, representing one of the higher CGA concentrations among Arabica cultivars, with primary isomers being 5-caffeoylquinic acid (5-CQA), 3-CQA, and 4-CQA. Caffeine content is moderate at 0.98–1.20% dry weight, consistent with Arabica species (lower than Robusta). Trigonelline, a niacin precursor, is present at approximately 0.6–1.2% in green beans, partially degrading to niacin (vitamin B3) during roasting. Total flavonoid content includes quercetin and kaempferol derivatives alongside condensed tannins. Crude protein in green beans is approximately 10–13% dry weight (predominantly non-essential amino acids; bioavailability low in roasted form). Total carbohydrates represent 60–65% dry weight in green beans, primarily sucrose (6–9%) and polysaccharides; sucrose degrades substantially during roasting. Lipid content is approximately 12–18% dry weight (coffee oil, primarily linoleic acid ~46%, palmitic acid ~30%), largely retained in the bean unless filtered. Minerals identified include potassium (~40 mg/100 mL brewed), magnesium (~7 mg/100 mL), and trace manganese. Dietary fiber (in whole bean): approximately 33–40% dry weight as arabinogalactans and mannans; negligible in brewed beverage. Bioavailability notes: CGAs in brewed coffee are moderately bioavailable (absorption ~30–70% in small intestine), with colonic microbiota further metabolizing remainder to phenylpropionic acids; caffeine is highly bioavailable (~99%); most lipids are retained in unfiltered preparations (e.g., French press) but removed by paper filtration. Roasting degree significantly degrades CGAs (up to 70% loss at dark roast) and converts trigonelline to niacin.
Preparation & Dosage
No clinically studied dosage ranges specific to Bali Kintamani coffee are documented. Standard coffee consumption guidelines would apply to this cultivar. Consult a healthcare provider before starting any new supplement.
Synergy & Pairings
Green tea extract, L-theanine, rhodiola, ginseng, CoQ10
Safety & Interactions
Bali Kintamani Coffee shares the safety profile of Coffea arabica broadly; caffeine at typical consumption levels (up to 400 mg/day for healthy adults) is generally recognized as safe, but doses exceeding this threshold may cause insomnia, tachycardia, anxiety, and elevated blood pressure. Caffeine is a CYP1A2 substrate and can interact with medications metabolized by this enzyme, including clozapine and theophylline, potentially raising their plasma concentrations; it also potentiates stimulant medications and may reduce the efficacy of adenosine-based antiarrhythmics. Pregnant individuals are advised to limit caffeine intake to under 200 mg/day due to associations between higher consumption and reduced fetal birth weight. Individuals with gastroesophageal reflux disorder, anxiety disorders, or arrhythmias should exercise caution due to chlorogenic acid-mediated gastric acid stimulation and caffeine's chronotropic effects.